Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesBotulinum toxin in the treatment of benign prostatic hyperplasia
Der Urologe, 08/11/08
Boy S et al. - An effect could be shown for different patient groups including different prostate sizes and different symptom characteristics. A high success rate and sustained duration of the effect of at least 12 months could be achieved. Side effects were marginal, and no systemic side effects were reported.
Related Articles
Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia
The Prostate, 11/18/09
Relevance Score: 82%
Resistive Index: A Newly Identified Predictor of Outcome of Transurethral Prostatectomy in Patients With Benign Prostatic Hyperplasia
Urology, 11/12/09
Relevance Score: 82%
Differences in Initial Benign Prostatic Hyperplasia Management Between Primary Care Physicians and Urologists
The Journal of Urology, 11/02/09
Relevance Score: 81%
Stone Formation in Prostatic Urethra After Potassium-Titanyl-Phosphate Laser Ablation of the Prostate for Benign Prostatic Hyperplasia
Journal of Endourology, 10/13/09
Relevance Score: 80%
Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world
Indian Journal of Urology, 10/08/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer
Cancer Science, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09
Article Search
Sponsor